{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:05:37Z","timestamp":1793048737476,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ejca.2022.10.003","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T13:08:23Z","timestamp":1666098503000},"page":"23-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer"],"prefix":"10.1016","volume":"178","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6488-4958","authenticated-orcid":false,"given":"Sibylle","family":"Loibl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Loirat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M.","family":"Tolaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1162-7963","authenticated-orcid":false,"given":"Kevin","family":"Punie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mafalda","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope S.","family":"Rugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Bardia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara A.","family":"Hurvitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8080-7960","authenticated-orcid":false,"given":"Adam M.","family":"Brufsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Kalinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce A.","family":"O'Shaughnessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Dieras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Gianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Gharaibeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Preger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"See","family":"Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9068-8504","authenticated-orcid":false,"given":"Martine J.","family":"Piccart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2022.10.003_bib1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.5306\/wjco.v12.i3.164","article-title":"Overview of recent advances in metastatic triple negative breast cancer","volume":"12","author":"O'Reilly","year":"2021","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.10.003_bib2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13058-019-1210-4","article-title":"Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review","volume":"21","author":"Li","year":"2019","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejca.2022.10.003_bib3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.breast.2018.03.002","article-title":"Global analysis of advanced\/metastatic breast cancer: decade report (2005-2015)","volume":"39","author":"Cardoso","year":"2018","journal-title":"Breast"},{"key":"10.1016\/j.ejca.2022.10.003_bib4","doi-asserted-by":"crossref","first-page":"28989","DOI":"10.18632\/oncotarget.25615","article-title":"The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target","volume":"9","author":"Goldenberg","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2022.10.003_bib5","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920915980","article-title":"Novel antibody-drug conjugates for triple negative breast cancer","volume":"12","author":"Nagayama","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejca.2022.10.003_bib6","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.10.003_bib7","series-title":"FDA grants regular approval to sacituzumab govitecan for triple-negative breast cancer","year":"2021"},{"key":"10.1016\/j.ejca.2022.10.003_bib8","series-title":"EORTC QLQ-C30 scoring manual","year":"2001"},{"key":"10.1016\/j.ejca.2022.10.003_bib9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jclinepi.2015.08.007","article-title":"Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust","volume":"69","author":"Giesinger","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ejca.2022.10.003_bib10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jnci\/94.1.39","article-title":"Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study","volume":"94","author":"Ganz","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2022.10.003_bib11","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1200\/JCO.2003.04.080","article-title":"Quality of life in a randomized trial of group psychosocial support in metastatic breast cancer: overall effects of the intervention and an exploration of missing data","volume":"21","author":"Bordeleau","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.10.003_bib12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10549-020-05602-9","article-title":"Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer","volume":"181","author":"Brandberg","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2022.10.003_bib13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2018.11.024","article-title":"General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States","volume":"107","author":"Nolte","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.10.003_bib14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.10.003_bib15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","article-title":"Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"29","author":"Cocks","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.10.003_bib16","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/pst.507","article-title":"Determining the non-inferiority margin for patient reported outcomes","volume":"10","author":"Gerlinger","year":"2011","journal-title":"Pharm Stat"},{"key":"10.1016\/j.ejca.2022.10.003_bib17","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","article-title":"Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"48","author":"Cocks","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.10.003_bib18","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12955-020-01344-w","article-title":"How is the minimal clinically important difference established in health-related quality of life instruments? Review of anchors and methods","volume":"18","author":"Mouelhi","year":"2020","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.ejca.2022.10.003_bib19","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1007\/s11136-015-1034-3","article-title":"Quality of life and metastatic breast cancer: the role of body image, disease site, and time since diagnosis","volume":"24","author":"McClelland","year":"2015","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ejca.2022.10.003_bib20","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.mcna.2017.06.003","article-title":"Long-term and latent side effects of specific cancer types","volume":"101","author":"Gegechkori","year":"2017","journal-title":"Med Clin N Am"},{"key":"10.1016\/j.ejca.2022.10.003_bib21","unstructured":"Rugo HS, Tolaney SM, Loirat D, Punie K, Bardia A, Hurvitz SA, et\u00a0al. Impact of UGT1A1 status on the safety profile of sacituzumab govitecan in the phase 3 ASCENT study in patients with metastatic triple-negative breast cancer [poster]. In: 43rd Annual San Antonio Breast Cancer Symposium (SABCS); virtual meeting, 8-11 December, 2020. San Antonio, TX2020."},{"key":"10.1016\/j.ejca.2022.10.003_bib22","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/onco.13878","article-title":"Sacituzumab govitecan for metastatic triple-negative breast cancer: clinical overview and management of potential toxicities","volume":"26","author":"Spring","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2022.10.003_bib23","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.annonc.2020.02.003","article-title":"Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer","volume":"31","author":"Adams","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.10.003_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159267","article-title":"Empirical evidence of study design biases in randomized trials: systematic review of meta-epidemiological studies","volume":"11","author":"Page","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2022.10.003_bib25","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.jval.2020.12.015","article-title":"Does knowledge of treatment assignment affect patient report of symptoms, function, and health status? An evaluation using multiple myeloma trials","volume":"24","author":"Roydhouse","year":"2021","journal-title":"Value Health"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922007997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922007997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:37:53Z","timestamp":1760733473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922007997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":25,"alternative-id":["S0959804922007997"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.10.003","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}